JAMES GULLEY

Nov 1, 2024 | jitc.bmj.com | JAMES GULLEY |Ryan Sullivan |Claire F. Friedman |P Sonpavde

AbstractBackground Invikafusp alfa, a dual T cell agonist, promotes the selective activation and expansion of Vβ6/Vβ10 TCR-expressing CD8+ and CD4+ effector memory T cells, which in nonclinical studies promote potent anti-tumor activity in anti-PD(L)1-resistant solid tumors.1 2Methods START001 is a first-in-human, multicenter Phase 1/2 study evaluating invikafusp as monotherapy in patients with anti-PD(L)1-resistant, antigen-rich solid tumors (TMB-H, MSI-H/dMMR, or virally associated).

Jul 3, 2024 | nature.com | Danh-Tai Hoang |Eldad D. Shulman |Doreen S. Ben-Zvi |Sanju Sinha |Neelam Sinha |Christopher Dampier | +12 more

AbstractAdvances in artificial intelligence have paved the way for leveraging hematoxylin and eosin-stained tumor slides for precision oncology. We present ENLIGHT–DeepPT, an indirect two-step approach consisting of (1) DeepPT, a deep-learning framework that predicts genome-wide tumor mRNA expression from slides, and (2) ENLIGHT, which predicts response to targeted and immune therapies from the inferred expression values.

Jun 25, 2023 | cgtlive.com | JAMES GULLEY

Thephase 1/2 START-001 trial (NCT05592626) is assessing intravenous infusion of STAR0602 once every 2 weeks in patients with checkpoint inhibitor (CPI)-resistant solid tumors. The phase 1 portion is a dose escalation through 8 provisional dose levels.

Jun 12, 2023 | onclive.com | JAMES GULLEY

James L. Gulley, MD, PhD, senior investigator, Center for Immuno-Oncology, acting clinical director, Center for Cancer Research, National Cancer Institute, discusses a phase 1 trial of PRGN-2009 alone and in combination with bintrafusp alfa (M7824) in patients with recurrent and/or metastatic HPV-associated cancers. At the 2023 ASCO Annual Meeting, investigators shared efficacy and safety findings for both PRGN-2009 alone and in combination with bintrafusp alfa, Gulley begins.